The coming months will be critical in defining who dominates Indias semaglutide market in the post-patent era
In November 2023, AstraZeneca and Eccogene signed an exclusive license agreement for ECC5004, an investigational oral once-daily GLP-1RA for treating obesity, type 2 diabetes, and other cardiometabolic conditions
PlexusDx connects patients with medical professionals trained in managing semaglutide protocols and side effect mitigation
70 At 3 weeks, the pain scores of both groups had significantly decreased from 5.6 and 5.1, respectively, to 0.9 in both groups, with no difference between groups
MHRA updates guidance for GLP-1 prescribers and patients
Convenient Access With both in-person and virtual consultation options, DrWell makes it easy to get the care you need, when you need it